Drugs / PSD502
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01184105 | Sep → Nov 2010 | premature ejaculation | Plethora Solutions Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01183208 | Dec 2009 → Feb 2010 | premature ejaculation | Plethora Solutions Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00483990 | Mar → Jun 2007 | — | Plethora Solutions Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSD502 | “A phase I, single-center, double-blind, randomized, placebo-controlled, safety and pharmacokinetic study to evaluate systemic and local vaginal exposure to lidocaine and...” NCT01184105 ↗ |
| Modality | Other / unclassified | “The study drug is a metered-dose anesthetic spray” NCT01184105 ↗ |
| Route | Topical | “PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis” NCT00483990 ↗ |